Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden

Fig. 1

Frequently silenced cancer-related gene amplifications (TCGA). Top panel: cancer-related genes that are amplified in ≥ 5% (N ≥ 34) of the tumor samples (N = 675) and silenced in ≥ 10% of those cases (N ≥ 4). Black = amplified, not silenced; grey = amplified and silenced. Bottom panel (starting with CCND1): sampling of common potentially actionable oncogenes; they are infrequently silenced. *Genes preceded by an asterisk were exclusively found to be focally amplified. Gene level amplification included those genes with ≥ 6 copies; RNA silencing was defined by ≥ 80% expression decrease in the tumor sample compared to the normal sample, including only tumor samples that had high-level amplification for that gene (≥ 6 copies of the gene); non-focal amplifications referred to co-amplification of genes located in the same 0.1 megabase genomic window

Back to article page